This article is more than 5 years old. Information may no longer be current.
VIDEO: ‘Explosion of options’ in single-tablet regimens for HIV benefits patients, providers
The biggest development in ART in the last several years has been “the explosion of options in single-tablet regimens,” according to Robert M. Grossberg, MD, associate professor of clinical medicine at Albert Einstein College of Medicine and medical director of the Montefiore Center for Positive Living/Infectious Diseases Clinic, both in the Bronx, NY.
There are now 5 single-tablet regimens available for patients who have never been treated with ART, according to Grossberg. He reviews the different medications in these regimens, as well as the developments that led to their availability. In particular, Grossberg highlights the advantages of tenofovir alafenamide, the new formulation of tenofovir, and boosted protease inhibitors.
He also discusses factors physicians should consider when developing regimens for patients who are ART-naive, including hepatitis B status and HIV viral load.
“Beyond that, I think the choice of regimens is fairly simple,” Grossberg said. “All these combinations work very well, so there’s little doubt that whatever you choose is going to be efficacious.”